Trump Wants Generics Made in America by 2028. The Economics Say They Can’t.
Trump gave generic drugmakers until August 2028 before a 100% tariff, rising to 200% in 2029. The problem is the margin those drugs actually carry.
Legal & Policy
Novo Is Suing Lilly Over a Head-to-Head Trial Lilly Won, Arguing the Result Went Stale
Novo Nordisk filed a Lanham Act suit over Lilly’s Zepbound ads, arguing a genuine head-to-head result became misleading once a higher Wegovy dose launched.
Sprouts Launches Bold Lawsuit Challenging Insulin Pricing
Sprouts files lawsuit over insulin pricing scheme and PBM collusion.
FDA’s BsUFA III Framework: What It Means for Biosimilar Sponsors
FDA defines biosimilar PAS & CBE under BsUFA III
Judge Rules ReWalk Device Is Medically Necessary for Medicare
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
J&J Faces $442M Treble Damages Over Catheter Monopoly
J&J’s $147M antitrust penalty tripled to $442M for monopolizing cardiac catheter market.